An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Trial ID #	NCT03699449
Phase	II
Drug Class	Immunotherapy: Checkpoint Inhibitors/PD-L1
Drug Name	Durvalumab
Alternate Drug Names	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi
Drugs in Trial	Durvalumab, Olaparib
Eligible Participant	Platinum resistant ovarian cancer
Patients Enrolled	Arm B: 14 HRRm Pt-R ovarian cancer, median 4 prior therapies
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, evaluated per RECIST
Biomarkers	HRRm panel: ATM, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCL, PALB2, PPP2R2A, RAD51 B/C/D, RAD54L
Efficacy	ORR: 35.7% (5PR, n=14) - all responders BRCA1/2 MUT
Conclusion	Durvalumab+olaparib shows promising activity in BRCA MUT patients
Reference	Lee J-Y et al. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION). J Clin Oncol (2021) 39 (suppl 15; abstr 5520) https://meetinglibrary.asco.org/record/195558/abstract Lee J-Y et al. Poster https://www.clearityfoundation.org/wp-content/uploads/2021/06/AMBITION-study-poster-ASCO-2021-scaled.jpeg Lee J-Y et al. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. J Gynecol Oncol (2022) 33(4):e45 https://pubmed.ncbi.nlm.nih.gov/35320892/